Changes in these genes are identified in samples of melanomas of patients with a worse response to targeted therapy (time to progression (TTP) < 4 months; [24] and in patients with primary and acquired resistance to BRAF inhibitors [22,29]. The gene discussed is BRAF; the disease is melanoma.